RSV is a common contagious virus characterised by several mild, cold-like symptoms. Although most people recover within a week or two, the virus can cause severe illness in certain groups, including older adults, infants and those with certain underlying chronic conditions.
Pfizer’s Abrysvo is already approved in major markets, including the US and EU, to protect older adults against RSV as well as infants through maternal immunisation. However, there are currently no vaccines approved for use in adults aged 18 to 59 years.
